EMA Support for innovative veterinary medicines

The European Medicines Agency is a world-class regulator of medicines. Its scientific recommendations are vital to provide EU citizens with effective, safe and high-quality medicines and enable an environment in which companies can develop new medicines.

General support of innovation

EMA guidelines and stakeholder interaction

Supporting SMEs

Financial and administrative assistance to small and medium companies

Innovation Task Force (ITF) Briefing

Advice on how to advance innovative medicines

Minor Use Minor Species (MUMS) limited market designation and incentives

Assisting companies who develop medicines for limited markets

Scientific advice

Providing scientific advice to companies on the appropriate tests and studies in the development of a veterinary medicine

Presubmission meetings

Advice to companies on regulatory matters

Idea | R&D | MRL assessment | Marketing Authorisation | Post-authorisation

Novel Therapies & Technologies Working Party (NTWP)

Guidance to clarify regulatory and scientific requirements for categories of therapy that are new to veterinary medicine

Facilitating development of new veterinary medicines in Europe

The European Medicines Agency (EMA) protects and promotes public and animal health in Europe. Through EMA's Committee for Medicinal Products for Veterinary Use (CVMP), scientific experts from across the European Union assess veterinary medicines across their lifecycle and provide expertise on animal health and wellbeing.

New treatment options for animals in Europe are needed and the Agency has set up a number of tools to provide scientific and regulatory support to companies to encourage the development of innovative veterinary medicines.

In support of these efforts, in 2015 EMA established the Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT) to develop guidance on the requirements for authorisation of products that are new to veterinary medicine.